Standard & Poor’s has raised the outlook on the “A+” rating of SCOR SE and its main subsidiaries to “positive” as, according to S&P’s statement, “capital and earnings expected to rise due to very strong ERM”.
SCOR delivers a strong performance for the first nine months of 2013, recording net income of EUR 302 million.
SCOR delivers a strong performance for the first nine months of 2013, recording net income of EUR 302 million.
The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i
The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i
The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i
SCOR's results for the first nine months of 2013.
SCOR delivers a strong performance for the first nine months of 2013, recording net income of EUR 302 million
